1990
DOI: 10.1021/jm00168a043
|View full text |Cite
|
Sign up to set email alerts
|

Syntheses and platelet aggregation inhibitory and antithrombotic properties of [2-[(.omega.-Aminoalkoxy)phenyl]benzenes

Abstract: A series of [2-[(omega-aminoalkoxy)phenyl]ethyl]benzene derivatives were synthesized and evaluated for their ability to inhibit collagen-induced platelet aggregation in vitro and to protect experimental thrombosis in mice. The results showed that the compounds were in vitro inhibitors of collagen-induced platelet aggregation. Most of them were also effective in the mouse antithrombotic assay. The compounds were found to be potent antagonists to S2 serotonergic receptor, and good correlation (r = 0.85) between … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
29
0

Year Published

1993
1993
2020
2020

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 51 publications
(29 citation statements)
references
References 0 publications
0
29
0
Order By: Relevance
“…Kasho et al (15) demonstrated that 5-HT increased the production of type 4 collagen by cultured human mesangial cells through 5-HT 2A receptor, which was mediated by activation of protein kinase C and subsequent increase in transforming growth factor-␤ activity. Currently, sarpogrelate hydrochloride, a potent 5-HT 2A receptor antagonist that inhibits 5-HTinduced vasoconstriction and platelet aggregation (16), is used clinically as antiplatelet drugs for prevention of thrombosis in atherosclerotic disease. Takahashi et al (17) reported that sarpogrelate hydrochloride reduced the degree of UAE, indicating the potential usefulness of this agent for the protection of development and progression of diabetic nephropathy.…”
Section: -Correlation Between Log (Plasma 5-hiaa) Concentration and Pmentioning
confidence: 99%
“…Kasho et al (15) demonstrated that 5-HT increased the production of type 4 collagen by cultured human mesangial cells through 5-HT 2A receptor, which was mediated by activation of protein kinase C and subsequent increase in transforming growth factor-␤ activity. Currently, sarpogrelate hydrochloride, a potent 5-HT 2A receptor antagonist that inhibits 5-HTinduced vasoconstriction and platelet aggregation (16), is used clinically as antiplatelet drugs for prevention of thrombosis in atherosclerotic disease. Takahashi et al (17) reported that sarpogrelate hydrochloride reduced the degree of UAE, indicating the potential usefulness of this agent for the protection of development and progression of diabetic nephropathy.…”
Section: -Correlation Between Log (Plasma 5-hiaa) Concentration and Pmentioning
confidence: 99%
“…Sarpogrelate, which is a 5-HT 2 antagonist and was introduced as a therapeutic agent for treatment of isch- Gong/Nakamura/Hattori/Ohnuki/Rashid/ Nakazawa/Watanabe/Nagatomo emic diseases associated with thrombosis [8], has been demonstrated to be selective and to show high affinity for the 5-HT 2A subtype, lacking significant 5-HT 1 , 5-HT 3 , ß-adrenoceptor, histamine H 1 , H 2 and muscarinic M 3 antagonistic activity [9][10][11]. However, there have been no reports of the inhibitory effects of sarpogrelate on the contraction-relaxation of coronary arteries.…”
Section: Introductionmentioning
confidence: 99%
“…The change in ∆F was measured in patients with autoimmune Raynaud's phenomenon, SSc or MCTD after administering the serotonin (5-hydroxytryptamine) receptor antagonist salpogrelate 16 at a dose of 300 mg/day for 4 weeks. Measurements were taken in the same way as described in the section on measuring skin hardness before and after salpogrelate therapy.…”
Section: Measurement Of Treatment Efficacymentioning
confidence: 99%